Our top pick for
Harrow Health, Inc is a drug manufacturers-specialty & generic business based in the US. Harrow Health shares (HROW) are listed on the NASDAQ and all prices are listed in US Dollars. Harrow Health employs 133 staff and has a trailing 12-month revenue of around USD$46.9 million.
|Latest market close||USD$5.63|
|52-week range||USD$3.33 - USD$7.92|
|50-day moving average||USD$5.8358|
|200-day moving average||USD$5.8016|
|Wall St. target price||USD$12.5|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||USD$0.581|
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2021-01-08)||-27.17%|
|1 month (2020-12-16)||-0.53%|
|3 months (2020-10-15)||-3.92%|
|6 months (2020-07-15)||3.68%|
|1 year (2020-01-15)||-22.13%|
|2 years (2019-01-15)||-4.58%|
|3 years (2018-01-12)||204.32%|
|5 years (2016-01-15)||4.65%|
Valuing Harrow Health stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Harrow Health's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Harrow Health's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 10x. In other words, Harrow Health shares trade at around 10x recent earnings.
That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.
Harrow Health's EBITDA (earnings before interest, taxes, depreciation and amortisation) is USD$1.2 million.
The EBITDA is a measure of a Harrow Health's overall financial performance and is widely used to measure a its profitability.
|Revenue TTM||USD$46.9 million|
|Gross profit TTM||USD$34.4 million|
|Return on assets TTM||-1%|
|Return on equity TTM||-8.09%|
|Market capitalisation||USD$148.8 million|
TTM: trailing 12 months
There are currently 921,362 Harrow Health shares held short by investors – that's known as Harrow Health's "short interest". This figure is 10.2% up from 836,184 last month.
There are a few different ways that this level of interest in shorting Harrow Health shares can be evaluated.
Harrow Health's "short interest ratio" (SIR) is the quantity of Harrow Health shares currently shorted divided by the average quantity of Harrow Health shares traded daily (recently around 130689.64539007). Harrow Health's SIR currently stands at 7.05. In other words for every 100,000 Harrow Health shares traded daily on the market, roughly 7050 shares are currently held short.
However Harrow Health's short interest can also be evaluated against the total number of Harrow Health shares, or, against the total number of tradable Harrow Health shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Harrow Health's short interest could be expressed as 0.04% of the outstanding shares (for every 100,000 Harrow Health shares in existence, roughly 40 shares are currently held short) or 0.0384% of the tradable shares (for every 100,000 tradable Harrow Health shares, roughly 38 shares are currently held short).
A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against Harrow Health.
Find out more about how you can short Harrow Health stock.
We're not expecting Harrow Health to pay a dividend over the next 12 months.
Harrow Health's shares were split on a 1:5 basis on 8 February 2013. So if you had owned 5 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Harrow Health shares – just the quantity. However, indirectly, the new 400% higher share price could have impacted the market appetite for Harrow Health shares which in turn could have impacted Harrow Health's share price.
Over the last 12 months, Harrow Health's shares have ranged in value from as little as $3.33 up to $7.92. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Harrow Health's is 1.0383. This would suggest that Harrow Health's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).
Harrow Health, Inc., together with its subsidiaries, develops, produces, and sells medications for unmet needs primarily in the United States. The company primarily provides ophthalmology based formulations to physicians and patients; and sterile and non-sterile compounded medications. It also develops and commercializes therapeutics for treating ocular surface diseases; and non-intravenous sedation and anesthesia therapeutics for human medical procedures in hospital, outpatient, and in-office settings. Its products portfolio includes topical eye drop drug candidates, including SURF-100 and SURF-200; SURF-300, an oral capsule for treating patients suffering from ocular surface diseases, and DED signs and symptoms; Klarity drops to protect and rehabilitate the ocular surface pathology for patients with DED; MELT-100, a drug that is administered sublingually for conscious sedation during cataract surgery; MAY-66 that is used for the treatment of symptoms associated with Peyronie's disease; MAY-44, a non-estrogen topical analgesic gel; and other drug candidates for rare diseases. In addition, the company engages in the development of MAY-88, an oral anhydrous extend release suspension of pentosan polysulfate sodium for interstitial cystitis. The company was formerly known as Imprimis Pharmaceuticals, Inc. and changed its name to Harrow Health, Inc. in December 2018. Harrow Health, Inc. was founded in 1998 and is headquartered in San Diego, California.
Everything we know about the Home Point Capital Inc IPO, plus information on how to buy in.
Everything we know about the ALFI INC IPO, plus information on how to buy in.
Steps to owning and managing CDAY, with 24-hour and historical pricing before you buy.
Steps to owning and managing CPF, with 24-hour and historical pricing before you buy.
Steps to owning and managing CFFI, with 24-hour and historical pricing before you buy.
Steps to owning and managing BPY, with 24-hour and historical pricing before you buy.
Steps to owning and managing BANF, with 24-hour and historical pricing before you buy.
Steps to owning and managing AVDL, with 24-hour and historical pricing before you buy.
Steps to owning and managing TEAM, with 24-hour and historical pricing before you buy.
Steps to owning and managing AUDC, with 24-hour and historical pricing before you buy.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.